Top

Published in:

Open Access 01-03-2011 | Correspondence

Consistent Biochemical Data are Essential for Comparability of Botulinum Toxin Type A Products

Author: Andy Pickett

Published in: Drugs in R&D | Issue 1/2011

Excerpt

The recent article from Dr Frevert of Merz,[1] together with the accompanying commentary from Dr Sesardic of NIBSC,[2] makes a new contribution to the data available for clinical botulinum toxin type A (BoNT-A) products. However, in addition to the comments about the various technical aspects of the data provided by Dr Frevert, as described by Dr Sesardic,[2] one important and key factor about the BoNT-A products has not been mentioned. The units of each product are different, not interchangeable, and no fixed or established conversion ratio exists between them,[3‐5] regardless of what clinical data are presented. …

Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D 2010; 10 (2): 67–73PubMedCrossRef

Sesardic D. Is it possible to accurately determine content of botulinum neurotoxin type A in drug products? Drugs R D 2010; 10 (2): 91–2PubMedCrossRef

Dysport®. Summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/870/SPC/Dysport [Accessed 2011 Jan 28]

Botox®. Summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/112/SPC/BOTOX+100+Units [Accessed 2011 Jan 28]

Xeomin®. Summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/20666/SPC/Xeomin [Accessed 2011 Jan 28]

Bocouture®. Summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/23251/SPC/Bocouture [Accessed 2011 Jan 28]

Pickett A. Tribute to an enigma: the life and times of Ivan Clifford Hall 1885–1975 [presentation]. 44th meeting of the Annual Interagency Botulism Research Co-ordinating Committee meeting; 2007 Oct 14–18; Asilomar (CA)

Fang P-K, Raphael BH, Maslanka SE, et al. Analysis of genomic differences among Clostridium botulinum type A1 strains. BMC Genomics 2010; 11: 725PubMedCrossRef

Zhang L, Lin WJ, Li S, et al. Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain. Gene 2003; 315: 21–32PubMedCrossRef

10.

Panjwani N, O’Keeffe R, Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. The Botulinum Journal 2008; 1 (1): 153–66CrossRef

11.

Pickett A, Dodd S, Rzany B. Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther 2008; 10 (3): 181–3PubMedCrossRef

12.

Pickett A, Caird D. Comparison of type A botulinum toxin products in clinical use. J Clin Pharm Ther 2008; 33: 327–8PubMedCrossRef

13.

Pickett A. Dysport®: pharmacological properties and factors that influence toxin action. Toxicon 2009; 54 (5): 683–9PubMedCrossRef

14.

Friday D, Bigalke H, Frevert J. In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. Naunyn-Schmiedeberg’s Arch Pharm 2002; 365 Suppl. 2: R20

15.

Eisele K-H, Fink K, Vey M, et al. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. Epub 2010 Dec 30

16.

Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (Xeomin) in focal dystonia. Drugs 2007; 67 (5): 669–83PubMedCrossRef

17.

17. Quarta M. Seitenvergleich zweier botulinumtoxin-A-prä parate bei lateroorbitalen mimikfalten: doppelblindstudie Botox® versus Xeomin®. J Ästhet Chir 2009; 4: 1–4

Title: Consistent Biochemical Data are Essential for Comparability of Botulinum Toxin Type A Products
Author: Andy Pickett
Publication date: 01-03-2011
Publisher: Springer International Publishing
Published in: Drugs in R&D / Issue 1/2011
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI: https://doi.org/10.2165/11590750-000000000-00000

At a glance: The STEP trials

Springer Medicine

Consistent Biochemical Data are Essential for Comparability of Botulinum Toxin Type A Products

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2011

Brentuximab Vedotin

Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation

Pharmacokinetic Profile of Lesogaberan (AZD3355) in Healthy Subjects

Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of One US-Marketed and Two European-Marketed Epoetin Alfas

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole

Comparison of Dissolution Profiles and Serum Concentrations of Two Lamotrigine Tablet Formulations